MedTrace Logo

An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis

NCT01561521 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2013-07-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate the onset and duration of action of two concentrations of AKF-1 Ophthalmic Solution compared to vehicle in the conjunctival allergen challenge (CAC) model of acute allergic conjunctivitis.

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

AKF-1

1 drop AKF-1 0.025% in each eye at 2 separate times during a 14 day period

DRUG

AKF-1

1 drop AKF-1 0.035% in each eye at 2 separate times during a 14 day period

DRUG

AKF-1

1 drop 0% in each eye at 2 separate times during a 14 day period

Sponsors & Collaborators

  • Akorn, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01561521 on ClinicalTrials.gov